Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05496374 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease
A Phase 2 study, sponsored by Spero Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT05496374 is a Phase 2 study that has completed, run by Spero Therapeutics. The registered enrollment target is 25 participants.
The verdict
NCT05496374, a Phase 2 study, has completed, sponsored by Spero Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate 1. The microbiological response and clinical efficacy of SPR720 compared with placebo in participants with nontuberculous mycobacteria pulmonary disease (NTM-PD). 2. The safety and tolerability of SPR720 in participants with NTM- PD 3. The pharmacokinetic (PK) of SPR719, active moiety, following orally (po) administered prodrug SPR720 in participants with NTM-PD.
Interventions
- DRUG Placebo
- DRUG SPR720 500 mg
- DRUG SPR720 1000 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2024-12-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05496374
The ClinicalTrials.gov registry entry for NCT05496374 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spero Therapeutics, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05496374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05496374 about?
NCT05496374 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease". The purpose of the study is to evaluate 1. The microbiological response and clinical efficacy of SPR720 compared with placebo in participants with nontuberculous mycobacteria pulmonary disease (NTM-PD). 2. The safety and tolerability of SPR720 in participants with NTM- PD 3. The pharmacokinetic (PK...
What is the current status of trial NCT05496374?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2022-12-14. Estimated completion is 2024-12-02.
What interventions are being tested in trial NCT05496374?
The interventions under investigation include: Placebo (DRUG), SPR720 500 mg (DRUG), SPR720 1000 mg (DRUG).
Who is sponsoring clinical trial NCT05496374?
This trial is sponsored by Spero Therapeutics, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.